301015 百洋医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)9.25019.62326.26727.42522.722
总资产报酬率 ROA (%)2.7926.23610.22312.44010.518
投入资产回报率 ROIC (%)3.4758.07013.68615.94812.901

边际利润分析
销售毛利率 (%)39.84037.47135.50333.29527.761
营业利润率 (%)9.5259.80812.07912.6418.979
息税前利润/营业总收入 (%)11.24111.06512.82013.2469.547
净利润/营业总收入 (%)7.8657.6199.4769.3356.523

收益指标分析
经营活动净收益/利润总额(%)100.87292.15695.70697.201101.354
价值变动净收益/利润总额(%)-1.46112.8576.3034.398-1.327
营业外收支净额/利润总额(%)-0.262-1.838-1.149-1.519-0.854

偿债能力分析
流动比率 (X)1.4291.4381.5692.1401.635
速动比率 (X)1.1211.2121.2841.7801.386
资产负债率 (%)65.79466.20163.37951.39154.688
带息债务/全部投入资本 (%)60.98859.73452.59637.05940.604
股东权益/带息债务 (%)60.72763.78885.200162.285137.491
股东权益/负债合计 (%)45.59745.86552.68387.66083.671
利息保障倍数 (X)6.4567.71714.59416.66814.817

营运能力分析
应收账款周转天数 (天)70.38980.10190.46191.82293.134
存货周转天数 (天)87.07369.92361.69749.41242.270